Literature DB >> 12519415

Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?

D Hadjidakis1, S Tsagarakis, C Roboti, M Sfakianakis, V Iconomidou, S A Raptis, N Thalassinos.   

Abstract

OBJECTIVE: Subclinical hypercortisolism (SH) is detected increasingly in a substantial proportion of patients with incidentally discovered adrenal adenomas. The clinical implications of SH are currently unclear. Osteoporosis is a well-known complication of glucocorticoid excess. So far, the impact of SH on bone mineral density (BMD) has been studied in a limited number of reports with discordant results. In the present study we evaluated the BMD in a large cohort of post-menopausal women with adrenal incidentalomas. : patients and measurements Forty-two post-menopausal women with incidentally discovered adrenal masses and radiological features highly suggestive of benign adrenal adenomas were investigated. All patients underwent a standard low-dose dexamethasone suppression test (LDDST; 0.5 mg 6-hourly for 2 days). The diagnosis of subclinical hypercortisolism (SH) was based on post-LDDST cortisol concentrations of > 70 nmol/l. According to this criterion patients were subdivided into two groups: with (n = 18; group A) or without (n = 24; group B) SH. There was no significant difference in age, years since menopause and body mass index between these groups. BMD was measured at L2-L4 vertebrae and three sites of the proximal femur by the dual energy X-ray absorptiometry (DEXA) method.
RESULTS: Post-menopausal women with SH (group A) exhibited slightly but significantly lower absolute and age-adjusted BMD values compared to group B patients in the femoral neck (BMD g/cm2: 0.72 +/- 0.08 vs. 0.79 +/- 0.09; Z-score: -0.20 +/- 0.82 vs. +0.43 +/- 0.94, P < 0.05) and trochanter (BMD g/cm2: 0.60 +/- 0.09 vs. 0.69 +/- 0.10; Z-score: -0.32 +/- 1.0 vs. +0.30 +/- 1.05, P < 0.01). BMD measurements of the Ward's triangle were also lower in group A patients but the difference did not reach statistical significance (BMD g/cm2: 0.60 +/- 0.10 vs. 0.68 +/- 0.13, P = 0.06). There was no difference in the lumbar vertebrae between the two groups (BMD g/cm2: 0.888 +/- 0.13 vs. 0.90 +/- 0.16, P = 0.78; z-score: +0.50 +/- 1.16 vs. +0.11 +/- 1.5, P = 0.36). The number of patients in the osteoporotic range was minimal with no significant difference between the two groups. However, the frequency of osteopenia in group A was significantly greater than in group B patients in the trochanter and Ward's triangle areas. Serum osteocalcin (BGP) levels were significantly lower in group A compared to group B patients (18.6 +/- 8.6 vs. 26.2 +/- 8.1 ng/ml, P < 0.01); no difference existed regarding parathyroid hormone (PTH) concentrations (43 +/- 15.6 vs. 41.2 +/- 14.8 pg/ml, P = 0.72).
CONCLUSIONS: In this series, post-menopausal women with subclinical hypercortisolism had lower absolute and age-adjusted BMD values and a higher rate of osteopaenia in the trabecular loaded and mixed cortical-trabecular bone of proximal femur. These data demonstrate that the subtle hypercortisolism of patients with adrenal incidentalomas may have an adverse effect on the bone mass of these patients.

Entities:  

Mesh:

Year:  2003        PMID: 12519415     DOI: 10.1046/j.1365-2265.2003.01676.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

Review 1.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Guidelines for the management of the incidentally discovered adrenal mass.

Authors:  Anil Kapoor; Topher Morris; Ryan Rebello
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

3.  Clinical and biochemical impact of BCL1 polymorphic genotype of the glucocorticoid receptor gene in patients with adrenal incidentalomas.

Authors:  M Tzanela; E Mantzou; K Saltiki; M Tampourlou; N Kalogeris; D Hadjidakis; S Tsagarakis; M Alevizaki
Journal:  J Endocrinol Invest       Date:  2011-07-05       Impact factor: 4.256

4.  The effects of cortisol and adrenal androgen on bone mass in Asians with and without subclinical hypercortisolism.

Authors:  S H Ahn; J H Kim; Y Y Cho; S Suh; B-J Kim; S Hong; S H Lee; J-M Koh; K-H Song
Journal:  Osteoporos Int       Date:  2019-02-04       Impact factor: 4.507

Review 5.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

Review 6.  Adrenal incidentalomas and subclinical Cushing's syndrome.

Authors:  Dima Abdelmannan; David C Aron
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

Review 7.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

8.  The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers.

Authors:  Shobana Athimulam; Danae Delivanis; Melinda Thomas; William F Young; Sundeep Khosla; Matthew T Drake; Irina Bancos
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

Review 9.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

Review 10.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.